Stifel Financial Corp Has $43.58 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Stifel Financial Corp raised its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 24.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 326,140 shares of the life sciences company's stock after purchasing an additional 64,986 shares during the period. Stifel Financial Corp owned approximately 0.21% of Illumina worth $43,582,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its holdings in shares of Illumina by 188.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 13,373 shares of the life sciences company's stock worth $1,787,000 after acquiring an additional 8,739 shares during the period. Transatlantique Private Wealth LLC bought a new position in Illumina during the 4th quarter worth about $215,000. MML Investors Services LLC raised its stake in shares of Illumina by 10.8% in the 4th quarter. MML Investors Services LLC now owns 25,888 shares of the life sciences company's stock valued at $3,459,000 after purchasing an additional 2,515 shares during the period. Natixis acquired a new stake in shares of Illumina in the 4th quarter valued at about $174,000. Finally, MetLife Investment Management LLC boosted its position in shares of Illumina by 8.6% during the fourth quarter. MetLife Investment Management LLC now owns 89,418 shares of the life sciences company's stock worth $11,949,000 after buying an additional 7,083 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Performance

Shares of NASDAQ:ILMN traded down $0.26 during trading on Friday, reaching $77.35. 1,424,483 shares of the stock were exchanged, compared to its average volume of 2,286,599. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The stock has a 50-day moving average price of $82.02 and a 200-day moving average price of $118.05. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The firm has a market cap of $12.24 billion, a PE ratio of -10.07, a PEG ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. HSBC lowered Illumina from a "buy" rating to a "hold" rating and set a $100.00 target price on the stock. in a research report on Friday, February 28th. Morgan Stanley lowered their price objective on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 11th. Piper Sandler increased their target price on shares of Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Citigroup lowered their price target on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. Finally, Hsbc Global Res downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Illumina currently has an average rating of "Moderate Buy" and a consensus price target of $138.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.